Time for AbbVie to sharpen its pencil a fourth time

Borrowing a page from AstraZeneca's (AZN) playbook, Shire plc (SHPG) publishes its "Path to US$10B In Product Sales by 2020" as a clear message to AbbVie (ABBV) that it needs to substantially increase its offer if it wants the BOD to seriously consider it.

Shire emphasizes its accelerating top-line growth, enhanced profitability, rich pipeline and total shareholder returns as proof that current management is on the right track and that Shire's future is bright continuing as an independent company.

From other sites
Comments (3)
  • alexcampbello
    , contributor
    Comments (278) | Send Message
    What is the exchange rate for british pound to us dollars? Thnx
    23 Jun 2014, 08:22 AM Reply Like
  • JDoe20
    , contributor
    Comments (1410) | Send Message
    About $1.70 - the last bid was $236.66 per US ADR.
    23 Jun 2014, 10:29 AM Reply Like
  • R140362241
    , contributor
    Comments (7) | Send Message
    Go to google to find out
    23 Jun 2014, 09:38 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs